迈向疼痛精准医学:诊断生物标志物与药物重定位
研究采用分步发现、优先排序、验证及独立队列测试设计,在精神科患者中识别疼痛的血液基因表达生物标志物。发现MFAP3等标志物可预测疼痛状态及未来因疼痛就诊急诊,并基于标志物进行药物重定位分析提出候选药物。
要点
- MFAP3在发现与验证中证据最稳健,尤其对PTSD女性和男性疼痛预测强。
- 其他汇聚功能证据较好的标志物包括GNG7、CNTN1、LY9、CCDC144B和GBP1。
- 基于标志物基因表达特征重定位分析提示SC-560、阿莫沙平及吡哆醇等候选。
核心结论
- 识别出可预测疼痛状态及未来疼痛相关急诊就诊的血液基因表达生物标志物,个性化按性别和诊断可提升预测。
- MFAP3在发现和验证步骤中证据最稳健,是独立队列中疼痛的强预测因子。
研究设计与样本
- 采用分步发现、优先排序、验证及独立队列测试的设计。
- 研究对象为精神科患者,该群体共病疼痛障碍风险高且疼痛感知增强。
- 发现阶段使用有力的受试者内纵向设计。
主要发现
- 鉴定出预测疼痛状态的血液基因表达生物标志物,按性别和诊断个性化后对未来因疼痛急诊就诊预测更佳。
- MFAP3此前无疼痛相关文献证据,但经验性证据最稳健,尤其在PTSD女性和男性中为强预测因子。
- 其他总体汇聚功能证据最佳的疼痛相关标志物为GNG7、CNTN1、LY9、CCDC144B和GBP1。
- 部分已识别标志物是现有药物的靶点。
关键数值与推荐
- MFAP3在发现与验证步骤中证据最稳健,是独立队列中疼痛的强预测因子。
- 其他汇聚功能证据最佳的标志物包括GNG7、CNTN1、LY9、CCDC144B和GBP1。
- 生物信息学药物重定位分析产生候选包括SC-560(NSAID)、阿莫沙平(抗抑郁药)、吡哆醇(维生素B6)、氰钴胺(维生素B12)和芹菜素(植物黄酮)。
临床怎么用
- 基于血液基因表达标志物可能辅助精神科患者疼痛风险评估与个性化预测。
- 标志物基因表达特征可用于生物信息学药物重定位,提示疼痛治疗候选药物。
- 研究思路可能有助于缓解诊断和治疗困境,间接应对阿片类药物流行问题。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We endeavored to identify objective blood biomarkers for pain, a subjective sensation with a biological basis, using a stepwise discovery, prioritization, validation, and testing in independent cohorts design. We studied psychiatric patients, a high risk group for co-morbid pain disorders and increased perception of pain. For discovery, we used a powerful within-subject longitudinal design. We were successful in identifying blood gene expression biomarkers that were predictive of pain state, and of future emergency department (ED) visits for pain, more so when personalized by gender and diagnosis. MFAP3, which had no prior evidence in the literature for involvement in pain, had the most robust empirical evidence from our discovery and validation steps, and was a strong predictor for pain in the independent cohorts, particularly in females and males with PTSD. Other biomarkers with best overall convergent functional evidence for involvement in pain were GNG7, CNTN1, LY9, CCDC144B, and GBP1. Some of the individual biomarkers identified are targets of existing drugs. Moreover, the biomarker gene expression signatures were used for bioinformatic drug repurposing analyses, yielding leads for possible new drug candidates such as SC-560 (an NSAID), and amoxapine (an antidepressant), as well as natural compounds such as pyridoxine (vitamin B6), cyanocobalamin (vitamin B12), and apigenin (a plant flavonoid). Our work may help mitigate the diagnostic and treatment dilemmas that have contributed to the current opioid epidemic.
引用
- Niculescu AB, Le-Niculescu H, Levey DF, et al. Towards precision medicine for pain: diagnostic biomarkers and repurposed drugs. Mol Psychiatry. 2019. PMID: 30755720. doi:10.1038/s41380-018-0345-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。